Biotech Values

[DewDiligence]

BMY reports interim phase-2 data for all-oral regimen of BMS-790052 plus BMS-650032:

http://finance.yahoo.com/news/AllOral-Treatment-Regimen-of-bw-1182894066.html?x=0&.v=1

…treatment with a dual, all-oral direct-acting antiviral (DAA) regimen of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052) and the investigational NS3 protease inhibitor asunaprevir (BMS-650032) achieved undetectable viral load at 12 weeks post-treatment (SVR12) in 90% (n=9/10) of genotype 1b hepatitis C (HCV) patients who had previously not responded to peginterferon alfa and ribavirin (alfa/RBV). Serious adverse events occurred in two patients in this study, of which one led to treatment discontinuation.

This is a small phase-2 study in Japanese patients with genotype-1b; the clinicaltrials.gov listing is at http://clinicaltrials.gov/ct2/show/NCT01051414 .

BMS-790052, the NS5A inhibitor, is the drug that is being paired with VRUS’ PSI-7977 in an all-oral trial on which BMY and VRUS are collaborating (#msg-63589775, #msg-68669755).

The BMS-790052 and BMS-650032 combination was discussed at AASLD 2010 in #msg-55118600 and left something to be desired. Whether this combination can be resuscitated for genotype-1b patients or Japanese patients, specifically, is an open question.